BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will release its earnings data before the market opens on Wednesday, August 2nd. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.19) per share for the quarter.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. The company had revenue of $9.40 million for the quarter, compared to the consensus estimate of $6.13 million. During the same period last year, the company earned ($0.31) earnings per share. The firm’s revenue was up 95.8% compared to the same quarter last year. On average, analysts expect BioCryst Pharmaceuticals to post $-0.72 EPS for the current fiscal year and $-0.7 EPS for the next fiscal year.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ BCRX) opened at 5.04 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $2.95 and a 12-month high of $9.25. The firm’s market capitalization is $405.32 million. The stock has a 50 day moving average of $5.67 and a 200-day moving average of $6.42.

A number of research firms have issued reports on BCRX. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, June 27th. Noble Financial restated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. Finally, Needham & Company LLC restated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $8.29.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/26/biocryst-pharmaceuticals-inc-bcrx-scheduled-to-post-earnings-on-wednesday.html.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.